Optimistic Buy Rating for Ocular Therapeutix Amid Early-Stage NPDR Study and Wet AMD Potential
TipRanksApr 22 13:46
Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and Ocular Therapeutix (OCUL)
TipRanksApr 19 18:30
HC Wainwright & Co. : The Ocular Therapeutix (OCUL.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $16.00.
Zhitong FinanceApr 19 18:30
Ocular Therapeutix Analyst Ratings
BenzingaApr 19 18:27
HC Wainwright & Co. Reiterates Buy on Ocular Therapeutix, Maintains $16 Price Target
BenzingaApr 19 18:28
Analysts Offer Insights on Healthcare Companies: Walgreens Boots Alliance (WBA), Ocular Therapeutix (OCUL) and Elevance Health (ELV)
TipRanksApr 17 17:10
J.P. Morgan Securities: The Ocular Therapeutix (OCUL.US) rating was reaffirmed and adjusted from superior to superior market rating, with a target price of $24.00.
Zhitong FinanceApr 16 23:21
Ocular Therapeutix Analyst Ratings
BenzingaApr 16 23:10
Analysts Are Bullish on Top Healthcare Stocks: OptimizeRx (OPRX), Ocular Therapeutix (OCUL)
TipRanksApr 16 12:30
Ocular Therapeutix (OCUL) Gets a Buy From Piper Sandler
TipRanksApr 8 18:37
Analysts Offer Insights on Healthcare Companies: Ocular Therapeutix (OCUL), Marinus (MRNS) and Halozyme (HALO)
TipRanksApr 8 18:30
Ocular Therapeutix Analyst Ratings
BenzingaMar 13 23:32
JMP Securities Reiterates Market Outperform on Ocular Therapeutix, Maintains $24 Price Target
BenzingaMar 13 23:34
Buy Rating Affirmed for Ocular Therapeutix on Robust Revenue Growth and Clinical Trial Prospects
TipRanksMar 13 18:16
Analysts Offer Insights on Healthcare Companies: Ocular Therapeutix (OCUL), Adaptimmune Therapeutics (ADAP) and Arcutis Biotherapeutics (ARQT)
TipRanksMar 13 14:30
JMP Securities Adjusts Ocular Therapeutix's Price Target to $24 From $12, Maintains Market Outperform Rating
MT NewswiresMar 12 22:18
Ocular Therapeutix Analyst Ratings
BenzingaMar 12 22:08
Buy Rating Affirmed for Ocular Therapeutix on Strong Phase 3 Results and Strategic Focus
TipRanksMar 12 12:35
Balanced Outlook: Hold Rating on Ocular Therapeutix Amidst Trial Progress and Management Changes
TipRanksMar 12 07:35
Piper Sandler Maintains Overweight on Ocular Therapeutix, Raises Price Target to $15
BenzingaFeb 26 22:47
No Data
No Data